GSK acquires stake in Aspen for R3.5 billion
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is to acquire a 16% stake in Aspen Pharmacare and will divest eight specialist products to the South African-based pharmaceutical firm, as it expands into emerging markets.